University of Toledo U.S. Patents

This collection includes United States patents for inventions by UT faculty, students and staff that list UT/MCO/MUO as the original assignee (owner). These patents include those assigned to the University of Toledo as well as to the Medical College of Ohio/Medical University of Ohio prior to the merger in 2006. Only granted patents, not patent applications, are included. Use the 'Search within this Series' box to search for keywords in the authors, titles, or abstracts of the patents.

The University of Toledo, Technology Transfer Website

Xenoantigen-displaying anti-cancer vaccines and method of making
Compositions, methods of making, and methods of using, xenoantigen-displaying anti-cancer vaccines are described.
Compositions and methods of treatment of cancers
Described herein are compositions and methods useful to treat cancers. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits.
Compositions of A-8R peptide
The present invention provides materials and methods useful to treat various sGCa1-expressing cancers. Materials include peptides which interfere with sGCa1's pro-survival functions, thereby resulting in apoptosis of sGCa1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits.
sGCa1 inhibiting compositions
The present invention provides materials and methods useful to treat various sGCa1-expressing cancers. Materials include peptides which interfere with sGCa1's pro-survival functions, thereby resulting in apoptosis of sGCa1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits.
Treatment of cancers with A-8R peptide
The present invention provides materials and methods useful to treat various sGCa1-expressing cancers. Materials include peptides which interfere with sGCa1's pro-survival functions, thereby resulting in apoptosis of sGCa1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits.